Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: Bone density, mass, and strength of the radius, and wrist fracture

Menopause

Volumn 20, Issue 2, 2013, Pages 130-137

  Simon, James A ^a   Recknor, Christopher ^b   Moffett, Alfred H ^c   Adachi, Jonathan D ^d   Franek, Edward ^e   Lewiecki, E Michael ^f   McClung, Michael R ^g   Mautalen, Carlos A ^h   Ragi Eis, Sergio ⁱ   Nicholson, Geoffrey C ^j   Muschitz, Christian ^k   Nuti, Ranuccio ^l   Törring, Ove ^m   Wang, Andrea ⁿ   Libanati, Cesar ⁿ  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b United Osteoporosis Centers   (United States)

^c OB GYN Associates of Mid Florida   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^f UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^g OREGON OSTEOPOROSIS CENTER   (United States)

^h Centro de Osteopatias Medicas   (Argentina)

ⁱ CEDOES Centro de Diagnostico e Pesquisa   (Brazil)

^j UNIVERSITY OF QUEENSLAND   (Australia)

^k St Vincent Hospital   (Austria)

^l UNIVERSITY OF SIENA   (Italy)

^m KAROLINSKA INSTITUTE   (Sweden)

ⁿ AMGEN INC   (United States)

more..

Author keywords

Bone mineral density; Denosumab; Fracture; Osteoporosis; Radius; Strength

Indexed keywords

DENOSUMAB;

AGED; ARTICLE; BODY DENSITY; BODY MASS; CORTICAL BONE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MUSCLE STRENGTH; OSTEOPOROSIS; QUANTITATIVE ANALYSIS; RADIUS; RISK REDUCTION; SCORING SYSTEM; SKELETON; TRABECULAR BONE; WRIST FRACTURE;

ABSORPTIOMETRY, PHOTON; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; RADIUS; RADIUS FRACTURES; RANK LIGAND; RISK; TOMOGRAPHY, X-RAY COMPUTED; ULNA FRACTURES;

EID: 84873414622     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e318267f909     Document Type: Article

References (28)

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17: 1726-1733.
2. Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 2005;20:185-194.
3. Nguyen TV, Center JR, Sambrook PN, Eisman JA. Risk factors for proximal humerus, forearm, and wrist fractures in elderly men and women: the Dubbo Osteoporosis Epidemiology Study. Am J Epidemiol 2001;153:587-595.
4. Siris ES, Brenneman SK, Miller PD, Barrett-Connor E, Chen YT, Sherwood LM, et al. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and older: results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res 2004;19:1215-1220.
5. Oyen J, Brudvik C, Gjesdal CG, Tell GS, Lie SA, Hove LM. Osteoporosis as a risk factor for distal radial fractures: a case-control study. J Bone Joint Surg Am 2011;93:348-356.
6. Vogt MT, Cauley JA, Tomaino MM, Stone K, Williams JR, Herndon JH. Distal radius fractures in older women: a 10-year follow-up study of descriptive characteristics and risk factors. The study of osteoporotic fractures. J Am Geriatr Soc 2002;50:97-103.
7. Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, et al. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res 2008;23:1974-1982.
8. Steiniche T, Christiansen P, Vesterby A, Hasling C, Ullerup R, Mosekilde L, et al. Marked changes in iliac crest bone structure in postmenopausal osteoporotic patients without any signs of disturbed bone remodeling or balance. Bone 1994;15:73-79.
9. Firoozabadi R, Morshed S, Engelke K, Prevrhal S, Fierlinger A, Miclau T, et al. Qualitative and quantitative assessment of bone fragility and fracture healing using conventional radiography and advanced imaging technologiesVfocus on wrist fracture. J Orthop Trauma 2008;22:S83-S90.
10. Engelke K, Libanati C, Liu Y, Wang H, Austin M, Fuerst T, et al. Quantitative computed tomography (QCT) of the forearm using general purpose spiral whole-body CT scanners: accuracy, precision and comparison with dual-energy X-ray absorptiometry (DXA). Bone 2009;45: 110-118.
11. Genant HK, Engelke K, Hanley DA, Brown JP, Omizo M, Bone HG, et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010;47:131-139.
12. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000;157:435-448.
13. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93: 165-176.
14. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000;141:3478-3484.
15. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesisYinhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
16. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765.
17. Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010;25:1886-1894.
18. Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Torring O, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011;96:1727-1736.
19. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93:2149-2157.
20. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011;48:677-692.
21. Ominsky MS, Stouch B, Schroeder J, Pyrah I, Stolina M, Smith SY, et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone 2011;49:162-173.
22. Seeman E, Libanati C, Austin M, et al. The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: a distinctive attribute of denosumab therapy [Abstract 1064]. J Bone Miner Res 2011;24:S22.
23. Augat P, Lida H, Jiang Y, Diao E, Genant HK. Distal radius fractures: mechanisms of injury and strength prediction by bone mineral assessment. J Orthop Res 1998;16:629-635.
24. Augat P, Fuerst T, Genant HK. Quantitative bone mineral assessment at the forearm: a review. Osteoporos Int 1998;8:299-310.
25. Melton LJ III, Riggs BL, van Lenthe GH, Achenbach SJ, Muller R, Bouxsein ML, et al. Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. J Bone Miner Res 2007;22:1442-1448.
26. Muller ME, Webber CE, Bouxsein ML. Predicting the failure load of the distal radius. Osteoporos Int 2003;14:345-352.
27. Melton LJ III, Christen D, Riggs BL, Achenbach SJ, Muller R, van Lenthe GH, et al. Assessing forearm fracture risk in postmenopausal women. Osteoporos Int 2010;21:1161-1169.
28. Dalzell N, Kaptoge S, Morris N, Berthier A, Koller B, Braak L, et al. Bone micro-architecture and determinants of strength in the radius and tibia: age-related changes in a population-based study of normal adults measured with high-resolution pQCT. Osteoporos Int 2009;20: 1683-1694.